The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Updated results from KOMET-007: ziftomenib plus aza-ven in R/R NPM1-m or KMT2A-r AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses the updated results from the KOMET-007 trial (NCT05735184) investigating the menin inhibitor ziftomenib in combination with azacitidine and venetoclax (aza-ven) in relapsed/refractory (R/R) NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Dr Fathi highlights the combination’s tolerability and promising response rates, and notes that the regimen demonstrated a relatively low incidence of differentiation syndrome. He expresses enthusiasm for the potential of this combination in both the R/R and upfront settings. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Ziftomenib is one of the menin inhibitors that is currently in clinical trials. It’s also one of two menin inhibitors that has recently been approved by the FDA for use, specifically ziftomenib, for relapsed/refractory MPN1-mutated disease. But that’s monotherapy. And trials are now emerging that are combining ziftomenib, the menin inhibitor, with conventional treatments, both intensive induction chemotherapy as well as azacitidine and venetoclax...
Ziftomenib is one of the menin inhibitors that is currently in clinical trials. It’s also one of two menin inhibitors that has recently been approved by the FDA for use, specifically ziftomenib, for relapsed/refractory MPN1-mutated disease. But that’s monotherapy. And trials are now emerging that are combining ziftomenib, the menin inhibitor, with conventional treatments, both intensive induction chemotherapy as well as azacitidine and venetoclax. And at this year’s ASH, there is going to be presentations on the combination of ziftomenib plus azacitidine and venetoclax, both in the relapsed/refractory setting as well as in the upfront setting.
So I’ll be presenting the data on the relapsed/refractory setting. We found that in general, the combination was quite well tolerated. There was a relatively low number of differentiation syndrome episodes, which is an adverse event of interest and concern for menin inhibitors in general as a class. The response rates were quite promising for a relapsed/refractory patient population. Many of our patients received transplant in prior lines of treatment as well as venetoclax. So in general, I think the data is promising. And I also look forward to seeing Dr Roboz’s presentation on the upfront setting where I think a lot of these combinations are going.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
